Oxford Pharmascience Group plc - Company update | Broadcast | BRR Media

Oxford Pharmascience Group plc - Company update

OXP Fri, 22 Apr 2016, 10:00am BST

Marcelo Bravo, Chief Executive, provides an update on the Company and recent progress with the plans to commercialise its non-steroidal anti-inflammatory drug (NSAID) molecules, known as OXPzero™.

Marcelo Bravo

Chief Executive Officer

Company Events - OXFORD PHARMASCIENCE GROUP

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience - Company update

Marcelo Bravo, Chief Executive Officer

Wed, 25 Jan 2017, 11:00am GMT

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience - Interim results 2016

Marcelo Bravo, Chief Executive Officer

Tue, 13 Sep 2016, 12:15pm BST

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience Group plc - Company update...

Marcelo Bravo, Chief Executive Officer

Fri, 22 Apr 2016, 10:00am BST

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience - Successful completion of PoC for...

Marcelo Bravo, Chief Executive Officer

Thu, 5 Nov 2015, 8:00am GMT

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Preliminary PK Data & Initiation of Further Study...

Marcelo Bravo, Chief Executive Officer

Wed, 12 Aug 2015, 3:00pm BST